PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34632715-6 2022 In BCL2-negative lymphoma cells, instead, killing by IACS-010759 was potentiated by the Mcl-1 inhibitor S63845. S63845 104-110 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 88-93 34728569-2 2022 S63845 is a highly specific inhibitor of MCL1. S63845 0-6 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 41-45 34707185-7 2021 Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells. S63845 37-43 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 12-17 34707185-7 2021 Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells. S63845 37-43 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 96-101 34675185-8 2021 FASN inhibition, however, fails to sensitize breast cancer cells to MCL-1- and BCL-XL-selective inhibitors such as S63845 and A1331852. S63845 115-121 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 68-73 34767916-5 2022 In this study, we investigate the Mcl-1 inhibitor S63845 in combination with venetoclax in AML cells. S63845 50-56 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 34-39 34564697-0 2021 Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells. S63845 65-71 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 50-54 34103421-7 2021 The combination of a NAMPT inhibitor (FK866) and an MCL-1 antagonist (S63845) reduced tumor growth in a TNBC patient-derived xenograft model in vivo. S63845 70-76 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 52-57 34568318-8 2021 To overcome this adaptation, we employed the BH3 mimetic S63845, a specific MCL-1 inhibitor, and evaluated its sequential addition to both kinase inhibitors to overcome resistance. S63845 57-63 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 76-81 34331013-5 2021 Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845. S63845 195-201 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 180-184 34385422-4 2021 Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845. S63845 91-97 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 18-22 34385422-4 2021 Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845. S63845 91-97 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 75-79 34385422-7 2021 Further studies indicated that cells with preformed BAK/MCL1 complexes were sensitive to the paclitaxel/S63845 combination, while cells without BAK/MCL1 complexes were not. S63845 104-110 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 56-60 33564073-9 2021 Moreover, combination of ETC-168 and MCL1 inhibitor S63845 exerts a synergistic antiproliferative activity against STS cells. S63845 52-58 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 37-41 35393436-5 2022 Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo. S63845 42-48 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 26-31 33690800-3 2021 BH3 profiling demonstrates their addiction to MCL1 (myeloid cell leukemia-1), which can be targeted with the small molecule inhibitor S63845. S63845 134-140 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 52-75 33540760-5 2021 RESULTS: AML cell lines were variably susceptible to PTC596 and to combination treatments with PTC596 and MCL1 inhibitor S63845, MEK inhibitor trametinib, or TP53 activator APR-246, independent of TP53 mutational status. S63845 121-127 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 106-110 33540760-8 2021 CONCLUSIONS: The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated MN1 gene expression and MCL1 protein levels, while PTC596 and trametinib may be more effective in CD34+ adverse risk AML with elevated BMI1 gene expression and MEK protein levels. S63845 43-49 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 144-148 32659848-3 2020 We thus tested the anti-leukemic activity of S63845, a specific MCL-1 inhibitor. S63845 45-51 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 64-69 32724460-7 2020 RESULTS: We found that highly potent and specific Mcl-1 inhibitors such as S63845 overcame regorafenib resistance by restoring apoptosis in multiple regorafenib-resistant CRC models. S63845 75-81 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 50-55 32990536-6 2021 In this review, we summarize the recent literature on small molecule and peptide inhibitors of Mcl-1, which are divided into different types including: peptide inhibitors, gossypol derivatives, marinopyrrole derivatives, S1 derivatives, indole derivatives, quinoline derivatives, S63845, AZD5991, AMG176, etc. S63845 280-286 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 95-100 32801295-6 2020 We validated this strategy in vivo using a RMS patient-derived xenograft model and observed a reduction in tumor growth with a tendency to stabilization with the sequential combination of vincristine and the MCL-1 inhibitor S63845. S63845 224-230 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 208-213 32801295-7 2020 We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845. S63845 200-206 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 130-135 32513939-0 2020 MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. S63845 16-22 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 0-4 31856269-3 2019 In this study, we investigated whether sensitivity to the novel MCL-1 inhibitor S63845 could be predicted using cytogenetics, focusing on amplification of 1q21, the chromosomal region that contains the MCL1 locus. S63845 80-86 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 64-69 32066201-0 2020 Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. S63845 27-33 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 38-42 32346617-11 2020 Co-inhibition of BCL-XL and MCL-1 with A1331852 and S63845 significantly inhibited cell proliferation of all four cell lines. S63845 52-58 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 28-33 31078737-6 2019 In contrast, the Mcl-1 inhibitor S63845 potently targeted basal-like, but not stem-like cells, highlighting dependency on distinct sentinel Bcl-2 family members. S63845 33-39 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 17-22 30214012-4 2019 We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845. S63845 182-188 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 167-171 30008477-0 2019 The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. S63845 28-34 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 4-8 28768804-4 2017 We tested the MCL-1 inhibitor S63845 in breast cancer cell lines and patient-derived xenografts with high expression of MCL-1. S63845 30-36 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 120-125 31004002-9 2019 Consequently, we tested an experimental treatment strategy based on cotargeting BCL2 with venetoclax and MCL1 with a highly specific small-molecule MCL1 inhibitor S63845. S63845 163-169 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 148-152 28768804-4 2017 We tested the MCL-1 inhibitor S63845 in breast cancer cell lines and patient-derived xenografts with high expression of MCL-1. S63845 30-36 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 14-19 27760111-0 2016 The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. S63845 19-25 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 4-8